Viridian Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Viridian Therapeutics, Inc. (VRDN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-269.95-237.73-129.87-79.41-110.72-41.87-32.70
Depreciation & Amortization1.240.840.260.120.24-0.140.28
Stock Based Compensation42.1567.1719.7714.473.650.000.00
Change in Working Capital9.60-9.4315.961.724.431.651.94
Change in Accounts Receivable0.100.000.35-0.450.000.000.00
Change in Accounts Payable-0.07-12.0411.521.66-0.430.000.00
Change in Other Working Capital9.866.600.26-0.124.850.000.00
Other Operating Activities-0.1561.970.267.496.304.310.38
Net Cash from Operating Activities-232.32-184.17-93.84-54.58-29.78-36.06-26.84
Investing Activities
Capital Expenditures-0.51-0.90-0.80-0.34-0.040.08-0.45
Acquisitions0.000.000.000.0029.370.000.00
Purchases of Investments-228.14-407.88-223.26-74.03-79.810.000.00
Sales/Maturities of Investments466.93314.53108.94-74.03-79.8128.31-29.46
Other Investing Activities0.000.000.000.000.000.000.00
Net Cash from Investing Activities-228.65-94.25-115.13-74.29-50.4828.23-29.91
Financing Activities
Debt Repayment0.000.00-0.450.00-10.29-2.330.00
Common Stock Issued459.68125.07291.87116.5925.102.2844.53
Common Stock Repurchased0.000.000.000.00-0.040.000.00
Other Financing Activities-26.94-12.32-22.51-8.28-6.18-0.08-3.04
Net Cash from Financing Activities457.74225.67322.24125.28101.310.0741.92
Summary
Net Change in Cash-3.23-52.75113.28-3.6021.05-7.76-14.84
Cash at Beginning of Period102.83155.5842.3045.9024.8532.6147.44
Cash at End of Period99.59-184.17155.5842.3045.9024.8532.61
Free Cash Flow-232.83-184.17-94.64-54.92-29.82-36.14-27.29
Supplemental Disclosures
Interest Paid1.820.890.290.000.270.510.49